trending Market Intelligence /marketintelligence/en/news-insights/trending/Ei9sFjHsu214Po_1OsRd6A2 content esgSubNav
In This List

Germany's Evotec to acquire privately held Just Biotherapeutics for $60M

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Germany's Evotec to acquire privately held Just Biotherapeutics for $60M

Evotec SE agreed to acquire Seattle-based private biotechnology company Just Biotherapeutics Inc. for an upfront cash payment of $60 million.

Just Biotherapeutics provides specialized services related to the development of drugs including design of processes, products and manufacturing plants. The company raised $14 million in a 2016 financing round that included investments by Bill & Melinda Gates Foundation, Merck & Co. Inc., Lilly Asia Ventures and ARCH Venture Partners LLC.

Hamburg, Germany-based Evotec, which provides drug discovery and development solutions, will pay another $30 million in milestone payments over the next three years.

Evotec expects to close the transaction in the second quarter of the year.

Just Biotherapeutics CEO James Thomas will join the combined company as executive vice president, global head of biotherapeutics and president of U.S. operations.